Search Results

Avitinib 2 mg  | 100.00%

TargetMol

Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]

More Information Supplier Page

Avitinib 100 mg  | 100.00%

TargetMol

Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This […]

More Information Supplier Page

Bendazac L-lysine 200 mg  | Purity Not Available

TargetMol

Bendazac L-lysine (Bendazaco lisina) is an agent introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.

More Information Supplier Page

Isoimperatorin 25 mg  | Purity Not Available

TargetMol

Isoimperatorin is an anti-inflammatory agent, exhibits significant inhibitory effects on acetylcholinesterase (AChE).

More Information Supplier Page